RaySearch Laboratories AB (publ)
STO:RAY B
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| SE |
|
RaySearch Laboratories AB (publ)
STO:RAY B
|
6.3B SEK |
Loading...
|
|
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD |
Loading...
|
|
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
29B USD |
Loading...
|
|
| AU |
|
Pro Medicus Ltd
ASX:PME
|
13.2B AUD |
Loading...
|
|
| JP |
|
M3 Inc
TSE:2413
|
1.1T JPY |
Loading...
|
|
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
4.8B USD |
Loading...
|
|
| US |
|
Doximity Inc
NYSE:DOCS
|
4.5B USD |
Loading...
|
|
| SE |
|
Sectra AB
STO:SECT B
|
34.9B SEK |
Loading...
|
|
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
23.6B CNY |
Loading...
|
|
| US |
V
|
Vocera Communications Inc
F:V00
|
2.4B EUR |
Loading...
|
|
| IN |
I
|
Inventurus Knowledge Solutions Ltd
NSE:IKS
|
243.3B INR |
Loading...
|
Market Distribution
| Min | -5 565 412.8% |
| 30th Percentile | -5.3% |
| Median | 3% |
| 70th Percentile | 7.5% |
| Max | 12 228% |
Other Profitability Ratios
RaySearch Laboratories AB (publ)
Glance View
RaySearch Laboratories AB is a medical technology company, which engages in the development of software solutions for improved radiation therapy of cancer. The company is headquartered in Stockholm, Stockholm. The company markets and sells its products mainly in the United States and in Europe through license agreements with medical technology companies and scientific institutions. As of December 31, 2011, 15 of the Company’s products were launched, including the software platform ORBIT (optimization of radiation therapy beams by iterative technique), which is available in its main products, and is a non-clinical system which functions as a research and development environment. Additionally, its solutions include software for optimizing Intensity Modulated Radiation Therapy (IMRT) plans for photons, adaptive technology for IMRT treatments and software for proton treatments. The Company’s commercial partners are Philips, Nucletron and IBA Dosimetry, among others. In April 2014, it established a German subsidiary, RaySearch Germany GmbH.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for RaySearch Laboratories AB (publ) is 16.9%, which is above its 3-year median of 12.1%.
Over the last 3 years, RaySearch Laboratories AB (publ)’s Net Margin has increased from 2.8% to 16.9%. During this period, it reached a low of 2.5% on Mar 31, 2023 and a high of 17.7% on Mar 31, 2025.
